Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Share Holder Update

Category: News & Announcements 2018By Richard Mollard July 31, 2018

Related posts

Top 20 Shareholders 30th December 2018
January 7, 2019

Top 20 Shareholders 14 December 2018
December 17, 2018

PharmAust Manufacturing Method Maintains Drug Potency
December 2, 2018

GMP Tablet Production for Clinical Trials Commences
November 13, 2018

2018 AGM Results
November 9, 2018

2018 AGM Presentation
November 9, 2018

Recent Articles

200921_PharmAust Awarded FightMND Grant for Phase I Trial
September 21, 2020
14 September, Shareholder Update
September 14, 2020
Elanco not to Exercise Agreed Option
September 9, 2020
Monepantel Anti-Covid-19 Activity Confirmed
September 9, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

👇👇👇

JP Equity Partners@jpequitypartner

Join @ausbiztv tomorrow at 9:20am EST / 7:20am WST to hear the Chief Scientific Officer of @PharmAust $PAA, Dr Richard Mollard deliver an update on the status of the development of the Company’s primary drug candidate, Monepantel (MPL).

Please join at: https://www.ausbiz.com.au/

Reply on Twitter 1309043218022105091 Retweet on Twitter 13090432180221050911 Like on Twitter 13090432180221050915 Twitter 1309043218022105091

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions